
Inhibikase Therapeutics (IKT) Stock Forecast & Price Target
Inhibikase Therapeutics (IKT) Analyst Ratings
Bulls say
Inhibikase Therapeutics is attractive because IKT-001 targets a clinically validated PAH biology with an oral prodrug designed to preserve imatinib’s anti-remodeling efficacy while improving the GI tolerability that constrained prior adoption. The adaptive Phase 3 IMPROVE-PAH program is already underway, with approvals in 28 countries, 79 of 180 sites activated, and a planned interim safety readout for Part A in 1H27, creating multiple near-term catalysts while potentially accelerating development by about 3 years. Financially, the company ended 3Q26 with $193.3M in cash, cash equivalents and marketable securities, reported a $0.10 per-share net loss, and appears funded through the conclusion of IMPROVE-PAH if warrant exercise proceeds as expected.
Bears say
Inhibikase Therapeutics is a high-risk clinical-stage company whose value depends overwhelmingly on IKT-001 succeeding in PAH, yet the program still must prove that a differentiated pharmacokinetic profile can improve tolerability without sacrificing efficacy. Historical imatinib data show meaningful safety concerns, including edema, bleeding, hepatic and hematologic events, with eight subdural hematomas reported across IMPRES and its extension, while IMPROVE-PAH excludes several high-risk populations and concomitant sotatercept, potentially narrowing the market and limiting combination positioning. The company also has a thin cash position, having raised $4M in May 2024 against $13.3M at YE2023, and faces dilution risk, delayed readouts, manufacturing and regulatory hurdles, and a more competitive PAH landscape that raises the bar for success.
This aggregate rating is based on analysts' research of Inhibikase Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Inhibikase Therapeutics (IKT) Analyst Forecast & Price Prediction
Start investing in Inhibikase Therapeutics (IKT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Inhibikase Therapeutics (IKT) Forecast
Inhibikase Therapeutics (IKT) Analyst Forecast & Price Prediction
Start investing in Inhibikase Therapeutics (IKT)
Order type
Buy in
Order amount
Est. shares
0 shares